News FDA hands another rejection to Replimune's melanoma therapy Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News Agios mulls early FDA filing for sickle cell therapy Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
R&D Overcoming 6 data management challenges in flow cytometry Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, making it fundamental to medical research.
News FDA points to liver injury with Amgen's Tavneos The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.
R&D Regulatory setback or scientific signal? The case for human-... Exploring a systemic challenge in translating biological promise into reliable human efficacy and safety.
News Anavex sinks after pulling Alzheimer's filing in EU Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned an EU filing for its Alzheimer's therapy.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
